← Back to jobs

Pediatric BMT Clinician

Emory University
FULL_TIME Remote · US Atlanta, GA, US Posted: 2026-05-11 Until: 2026-06-10
Apply Now →
You will be redirected to the original job posting on BeBee.
Apply directly with the employer.
Job Description
Discover Your Career at Emory University Emory University is a leading research university that fosters excellence and attracts world-class talent to innovate today and prepare leaders for the future. We welcome candidates who can contribute to the excellence of our academic community. Description The Aflac Cancer & Blood Disorders Center of Children’s Healthcare of Atlanta and the Emory University Department of Pediatrics invites interested applicants for a faculty level position in pediatric Blood and Marrow Transplantation. The Aflac Cancer & Blood Disorders Center provides a rich and collaborative environment for basic, clinical, and translational research and boasts a diverse faculty. The Blood and Marrow Transplant (BMT) Program is one of the largest pediatric BMT programs in the country, performing more than 80 lifesaving BMTs in 2024. The BMT program is an integral component of the Aflac Cancer & Blood Disorders Center, and currently includes 12 faculty members, with a broad range of basic, clinical and translational research. Qualified candidates should be Board Certified/Eligible Hematologist/Oncologists, and preference will be given to applicants who wish to continue a career focused on clinical care in transplantation and cellular therapy. This is a clinical position, and research commitment is flexible depending on the candidate’s qualifications. Rank of assistant or associate professor will depend on experience and accomplishments. About the Aflac Cancer & Blood Disorders Center The successful candidate will join one of the strongest pediatric hematology/oncology programs in the country. In 2024, the Aflac Cancer & Blood Disorders Center was ranked No. 12 in the nation for Pediatric Cancer by US News and World Report Each year our team cares for more than 170 newly diagnosed leukemia and lymphoma patients using a variety of treatment protocols, including b